Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Talphera (TLPH)
NASDAQ:TLPH
Holding TLPH?
Track your performance easily
Earnings Data
Report Date
Mar 06, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-0.17Last Year’s EPS
-0.25Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 02, 2018
|% Change Since: -24.72%
|Next Earnings Date:Aug 02, 2018
Earnings Call Sentiment|Neutral
The earnings call revealed positive progress in clinical trials, regulatory advantages, and strong investor support, but also highlighted challenges in patient enrollment and financial constraints that require additional capital.Company Guidance
During Talphera's Q3 2024 earnings call, significant guidance was provided on the ongoing NEPHRO CRRT study, particularly regarding patient enrollment and site expansion. Vincent Angotti, CEO, highlighted that the trial now includes five active clinical sites, with plans to increase to seven by the end of the year and up to 14 sites by early 2025, following FDA approval. The primary endpoint focuses on the mean activated clotting time within the first 24 hours, with trial completion expected within 72 hours per patient. Cash operating expenses for Q3 totaled $3.5 million, reflecting an increase due to the clinical study, with year-to-date expenses reaching $11.5 million and full-year projections between $15 million and $17 million. Cash reserves stood at $11.1 million, leading to the anticipation of additional capital requirements. To enhance enrollment, Talphera is optimizing screening processes and collaborating with high-volume CRRT sites, aiming to complete the study in 2025 with the potential for data release within the same year.Expansion of Clinical Trial Sites
The number of active clinical trial sites increased to five, with plans to expand to seven by the end of the year and 11 by next year. The FDA expanded the maximum number of trial sites from 10 to 14.
Progress in NEPHRO CRRT Study
The first patient was enrolled in August, and multiple patients have completed the trial. The company is taking measures to improve enrollment rates and activate additional study sites.
Clinical and Regulatory Advantages
Nafamostat has a 30-year track record of efficacy and safety in Japan and South Korea, minimizing clinical risk. The trial design has been agreed upon with the FDA, and the product candidate has a breakthrough designation, allowing for quicker review and response times.
Financial Support from Main Investor
Main investor Nantahala has expressed continued financing support for the clinical study.
---
TLPH Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
TLPH Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 13, 2024 | $0.89 | $0.66 | -25.84% |
| Aug 14, 2024 | $0.86 | $0.87 | +1.16% |
| May 14, 2024 | $1.02 | $1.22 | +19.61% |
| Mar 06, 2024 | $1.27 | $1.14 | -10.24% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Talphera (TLPH) report earnings?
Talphera (TLPH) is schdueled to report earning on Mar 06, 2025, TBA Not Confirmed.
What is Talphera (TLPH) earnings time?
Talphera (TLPH) earnings time is at Mar 06, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is TLPH EPS forecast?
TLPH EPS forecast for the fiscal quarter 2024 (Q4) is -0.17.
---